Akebia Therapeutics (US.AKBA)
资本配置审计 · 期间： 2012 – 2026
核心指标
US.AKBA · 同比： 2026 H1 vs 2025 H1
| 指标 | 数值 | 同比 |
|---|---|---|
| FCF Conversion | 123.4% | ↑ |
| ROE | -71.8% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 2.20 | ↓ |
| Gross Margin | 77.9% | ↓ |
US.AKBA (Akebia Therapeutics) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 123.4% ↑ ROE -71.8% ↓ Cash Conversion - → D/E Ratio 2.20 ↓ Gross Margin 77.9% ↓
核心指标
US.AKBA (Akebia Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 123.4% ↑ROE -71.8% ↓Cash Conversion - →D/E Ratio 2.20 ↓Gross Margin 77.9% ↓免费公司
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies